Last reviewed · How we verify
Lamotrigine polytherapy including valproate — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Lamotrigine polytherapy including valproate (Lamotrigine polytherapy including valproate) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lamotrigine polytherapy including valproate TARGET | Lamotrigine polytherapy including valproate | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lamotrigine polytherapy including valproate CI watch — RSS
- Lamotrigine polytherapy including valproate CI watch — Atom
- Lamotrigine polytherapy including valproate CI watch — JSON
- Lamotrigine polytherapy including valproate alone — RSS
Cite this brief
Drug Landscape (2026). Lamotrigine polytherapy including valproate — Competitive Intelligence Brief. https://druglandscape.com/ci/lamotrigine-polytherapy-including-valproate. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab